News
-
-
-
PRESS RELEASE
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
NanoViricides, Inc. receives Rare Pediatric Disease Drug (RPDD) Designation from US FDA for antiviral drug NV-387 for Measles treatment, offering potential Priority Review Voucher benefits. Drug shows promise against rising Measles cases globally -
-
-
-
-
-
PRESS RELEASE
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
NanoViricides, Inc. receives approval for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus in DR Congo, addressing lack of effective Ebola treatments -
